USA flag logo/image

An Official Website of the United States Government

Development of a plant-grown subunit vaccine against respiratory syncytial virus

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
95720
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
AI082834
Solicitation Year:
N/A
Solicitation Topic Code:
NIAID
Solicitation Number:
N/A
Small Business Information
VIROGENOMICS, INC.
12909 SW 68th Parkway TIGARD, OR -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: Development of a plant-grown subunit vaccine against respiratory syncytial virus
Agency: HHS
Contract: 1R43AI082834-01A1
Award Amount: $581,068.00
 

Abstract:

DESCRIPTION (provided by applicant): Respiratory syncytial virus (RSV)-caused disease represents a significant health care burden worldwide. The RSV infects virtually all children throughout the world in both developed and developing countries. Re-infecti on is common because natural infection does not induce lasting immunity. Also, severe RSV infections are increasingly occurring among the elderly. In spite of wide-scale efforts to produce an effective vaccine against RSV, no vaccine is yet available. D evelopment of an inexpensive edible plant-based oral vaccine is an innovative approach for the control of RSV. The present study extends the strategy of using a plant-based oral vaccine to a respiratory pathogen for the first time. Even if lasting immunity is not obtained with the plant-based vaccine, it would be relatively low in cost to use such a vaccine during successive RSV seasons. We have shown previously that oral immunization of mice with transgenic tomato fruit expressing an RSV- subunit protei n, i.e., the F-protein, induces a systemic immune response. This proof of principle Phase I study will optimize the expression of the RSV-F protein in the transgenic tomato fruit and determine the capacity of this orally-given antigenic protein to protec t against an RSV challenge in two commonly-used models for RSV studies, the Balb/c mouse and the cotton rat. Success will validate the further development of our tomato- based vaccine against RSV and set the stage for a Phase II study. Such a vaccine will definitely make a difference and have an enduring impact on human health. PUBLIC HEALTH RELEVANCE: Respiratory syncytial virus-caused disease is a significant health care burden worldwide, but no vaccine is available. We are developing an inexpensive v accine using tomato plants to control this virus.

Principal Investigator:

Renee L. Shirley
5036261144
RSHIRLEY@VIROGENOMICS.COM

Business Contact:


gil.miller@virogenomics.com
Small Business Information at Submission:

VIROGENOMICS, INC.
VIROGENOMICS, INC. 9020 SW WASHINGTON SQUARE RD TIGARD, OR -

EIN/Tax ID: 193131912
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No